The product Proviron (25 mg per tablet), manufactured by Optitropin, was independently tested to verify its potency. The sample, submitted by B Ware, an individual consumer with no commercial ties, was analyzed by Janoshik Analytical. The results confirmed that the sample contained 24.52 mg and 24.75 mg of Mesterolone per tablet in separate tests, representing 98.08% and 99% of the labeled claim of 25 mg.
Testing was initiated on 5 January 2024, with the sample received on 11 January 2024, and analysis conducted on the same day. The measured concentrations are within an acceptable pharmaceutical variance, confirming a high level of quality control for this batch.
This report is published to promote transparency and harm reduction, helping consumers make informed decisions regarding pharmaceutical product use.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Proviron
- Active Ingredient: Mesterolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #37375
- Testing Ordered: 5 January 2024
- Sample Received: 11 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|
| 25 mg (as per label) | 24.52 mg | 98.08% | -1.92% |
| 25 mg (as per label) | 24.75 mg | 99% | -1% |
Verification Details
- Verification URL: https://janoshik.com/tests/37375_8NPN8LT8PIZ3
Evaluation of Consumer-Submitted Testing
The analysis confirms that the Proviron (25 mg per tablet) sample meets its labeled claim, with measured concentrations of 98.08% and 99% accuracy. This minor deviation is within acceptable pharmaceutical tolerances, suggesting high-quality manufacturing standards for this batch.
As the sample was submitted by B Ware, an individual consumer with no known commercial ties, there is no potential bias from reseller or manufacturer submissions. However, as with any single-batch test, additional independent testing across multiple batches is advised to validate the consistency of the entire product line.
Conclusion
The results confirm that Optitropin’s Proviron (25 mg) meets its labeled potency, with measured concentrations of 24.52 mg and 24.75 mg per tablet. This reflects strong quality control for the tested batch, but regular third-party testing is recommended to ensure batch-to-batch consistency.
This report is provided to educate consumers and support harm reduction by facilitating informed decision-making regarding pharmaceutical products.
Disclaimer
This report is for educational and harm reduction purposes only. The results pertain solely to the batch tested and may not reflect the quality of other batches. Although B Ware has no commercial interests, readers are encouraged to critically assess this information alongside third-party or independent data to form a comprehensive understanding of product consistency. Always consult healthcare professionals and adhere to local regulations before using such products.
